Spinraza

Spinraza (nusinersen sodium) is a disease-modifying therapy developed for the treatment of spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord. SMA leads to progressive muscle weakness and atrophy, impacting essential functions such as movement, breathing, and swallowing. Spinraza works at the genetic level to address the underlying cause of the disease rather than only managing symptoms.
Nusinersen is an antisense oligonucleotide designed to increase the production of survival motor neuron (SMN) protein. In individuals with SMA, the SMN1 gene is defective or missing, resulting in insufficient SMN protein. Spinraza targets the SMN2 gene, modifying its splicing process so that it can produce more functional SMN protein. Increased levels of this protein help support the health and function of motor neurons, slowing disease progression and improving muscle function.
Spinraza is administered directly into the fluid surrounding the spinal cord through an intrathecal route. The treatment schedule typically includes an initial loading phase followed by maintenance doses at regular intervals. Clinical studies have shown that Spinraza can improve motor function, increase survival, and enhance quality of life in infants, children, and adults with different types of SMA, especially when treatment is started early.
Overall, Spinraza represents a significant advancement in the management of spinal muscular atrophy. By targeting the genetic mechanism of the disease, it offers hope for better long-term outcomes, improved mobility, and greater independence for individuals living with SMA.